These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34327137)

  • 21. CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors.
    Schettini F; De Santo I; Rea CG; De Placido P; Formisano L; Giuliano M; Arpino G; De Laurentiis M; Puglisi F; De Placido S; Del Mastro L
    Front Oncol; 2018; 8():608. PubMed ID: 30631751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting breast cancer with CDK inhibitors.
    Mayer EL
    Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
    Gul A; Leyland-Jones B; Dey N; De P
    Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer.
    Nabieva N; Fasching PA
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Role of CDK4/6 Inhibitors in Breast Cancer.
    Murphy CG
    Curr Treat Options Oncol; 2019 May; 20(6):52. PubMed ID: 31101994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.
    Sobhani N; D'Angelo A; Pittacolo M; Roviello G; Miccoli A; Corona SP; Bernocchi O; Generali D; Otto T
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profile of abemaciclib and its potential in the treatment of breast cancer.
    Martin JM; Goldstein LJ
    Onco Targets Ther; 2018; 11():5253-5259. PubMed ID: 30214230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future.
    Chen X; Xu D; Li X; Zhang J; Xu W; Hou J; Zhang W; Tang J
    J Cancer; 2019; 10(26):6608-6617. PubMed ID: 31777590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
    Spring LM; Wander SA; Andre F; Moy B; Turner NC; Bardia A
    Lancet; 2020 Mar; 395(10226):817-827. PubMed ID: 32145796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.
    Giuliani J; Bonetti A
    J Oncol Pharm Pract; 2020 Sep; 26(6):1486-1491. PubMed ID: 32576084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
    Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDK 4/6 inhibitors for adjuvant therapy in early breast cancer-Do we have a clear winner?
    Akhade A; Van Wambeke S; Gyawali B
    Ecancermedicalscience; 2022; 16():ed124. PubMed ID: 36200010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.
    Barroso-Sousa R; Shapiro GI; Tolaney SM
    Breast Care (Basel); 2016 Jun; 11(3):167-73. PubMed ID: 27493615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
    Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
    Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
    Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.